{
  "companies": [
    {
      "id": "YOUR_COMPANY_001",
      "name": "InnovatePharma Inc.",
      "type": "Pharma",
      "development_stage": "Marketed",
      "headquarters": "USA",
      "financial_status": "Public",
      "partner_status": "N/A",
      "territory": "Global"
    },
    {
      "id": "COMP-001",
      "name": "Competitor Co. 1",
      "type": "Biotech",
      "development_stage": "Phase 3",
      "headquarters": "USA",
      "financial_status": "Public",
      "partner_status": "Seeking Partners",
      "territory": "Global"
    },
    {
      "id": "COMP-002",
      "name": "Competitor Co. 2",
      "type": "Biotech",
      "development_stage": "Preclinical",
      "headquarters": "Europe",
      "financial_status": "Venture Backed",
      "partner_status": "N/A",
      "territory": "Europe"
    },
    {
      "id": "COMP-003",
      "name": "Competitor Co. 3",
      "type": "Pharma",
      "development_stage": "Phase 1",
      "headquarters": "Asia",
      "financial_status": "Public",
      "partner_status": "Partnered",
      "territory": "APAC"
    },
    {
      "id": "COMP-004",
      "name": "Competitor Co. 4",
      "type": "Biotech",
      "development_stage": "Phase 1",
      "headquarters": "USA",
      "financial_status": "Private",
      "partner_status": "Seeking Partners",
      "territory": "USA"
    },
    {
      "id": "COMP-005",
      "name": "Competitor Co. 5",
      "type": "CRO",
      "development_stage": "Phase 2",
      "headquarters": "Canada",
      "financial_status": "Private",
      "partner_status": "N/A",
      "territory": "Global"
    }
  ],
  "molecules": [
    {
      "id": "MOL-001",
      "name": "OncoTarget-1 (NSCLC)",
      "ndc_code": "NDC001",
      "asset_type": "Molecule",
      "development_stage": "Phase 2",
      "therapeutic_area": "Oncology",
      "indication": "Advanced NSCLC",
      "mechanism_of_action": "Kinase Inhibitor",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2029,
      "current_roi": null,
      "projected_peak_sales_M": 150.0,
      "internal_risk_score": 0.7,
      "efficacy_profile": "Moderate efficacy",
      "safety_profile": "Mild GI issues",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-002",
      "name": "NeuroSense (Alzheimer's)",
      "ndc_code": "NDC002",
      "asset_type": "Molecule",
      "development_stage": "Phase 3",
      "therapeutic_area": "Neuroscience",
      "indication": "Alzheimer's Disease",
      "mechanism_of_action": "GPCR Modulator",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2040,
      "current_roi": null,
      "projected_peak_sales_M": 2500.0,
      "internal_risk_score": 0.3,
      "efficacy_profile": "High efficacy",
      "safety_profile": "Well tolerated",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-003",
      "name": "CardioFix (Heart Failure)",
      "ndc_code": "NDC003",
      "asset_type": "Molecule",
      "development_stage": "Preclinical",
      "therapeutic_area": "Cardiovascular",
      "indication": "Chronic Heart Failure",
      "mechanism_of_action": "Enzyme Replacement",
      "route_of_administration": "Intravenous",
      "modality": "Biologic",
      "patent_expiry_year": 2043,
      "current_roi": null,
      "projected_peak_sales_M": null,
      "internal_risk_score": 0.2,
      "efficacy_profile": "Early promise",
      "safety_profile": "No issues yet",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-004",
      "name": "ImmunoBoost (Solid Tumors)",
      "ndc_code": "NDC004",
      "asset_type": "Molecule",
      "development_stage": "Phase 1",
      "therapeutic_area": "Oncology",
      "indication": "Advanced Solid Tumors",
      "mechanism_of_action": "Immunomodulator",
      "route_of_administration": "Intravenous",
      "modality": "Monoclonal Antibody",
      "patent_expiry_year": 2037,
      "current_roi": null,
      "projected_peak_sales_M": 800.0,
      "internal_risk_score": 0.4,
      "efficacy_profile": "Good early response",
      "safety_profile": "Some infusion reactions",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-005",
      "name": "OldSchoolRx (T2D)",
      "ndc_code": "NDC005",
      "asset_type": "Molecule",
      "development_stage": "Phase 2",
      "therapeutic_area": "Metabolic",
      "indication": "Type 2 Diabetes",
      "mechanism_of_action": "GPCR Modulator",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2027,
      "current_roi": 0.1,
      "projected_peak_sales_M": 80.0,
      "internal_risk_score": 0.9,
      "efficacy_profile": "Inferior to new SOC",
      "safety_profile": "Common GI issues",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-006",
      "name": "RareCure-1 (Orphan X)",
      "ndc_code": "NDC006",
      "asset_type": "Molecule",
      "development_stage": "Phase 1",
      "therapeutic_area": "Rare Diseases",
      "indication": "Orphan Disease X (Gene Therapy)",
      "mechanism_of_action": "Gene Therapy",
      "route_of_administration": "Intravenous",
      "modality": "Gene Therapy",
      "patent_expiry_year": 2047,
      "current_roi": null,
      "projected_peak_sales_M": null,
      "internal_risk_score": 0.2,
      "efficacy_profile": "Early promise",
      "safety_profile": "Monitoring",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "MOL-007",
      "name": "DermSolution (Psoriasis)",
      "ndc_code": "NDC007",
      "asset_type": "Molecule",
      "development_stage": "Marketed",
      "therapeutic_area": "Dermatology",
      "indication": "Psoriasis",
      "mechanism_of_action": "Immunomodulator",
      "route_of_administration": "Topical",
      "modality": "Small Molecule",
      "patent_expiry_year": 2032,
      "current_roi": 0.25,
      "projected_peak_sales_M": 300.0,
      "internal_risk_score": 0.3,
      "efficacy_profile": "Good market uptake",
      "safety_profile": "Well tolerated",
      "is_for_sale": false,
      "company_id": "YOUR_COMPANY_001",
      "company_name": "InnovatePharma Inc."
    },
    {
      "id": "COMP-MOL-001",
      "name": "SuperieurRx (T2D)",
      "ndc_code": "NDC100",
      "asset_type": "Molecule",
      "development_stage": "Phase 3",
      "therapeutic_area": "Metabolic",
      "indication": "Type 2 Diabetes",
      "mechanism_of_action": "GPCR Modulator",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2035,
      "current_roi": 0.3,
      "projected_peak_sales_M": 1500.0,
      "internal_risk_score": 0.1,
      "efficacy_profile": "Superior efficacy, fewer side effects",
      "safety_profile": "Very well tolerated",
      "is_for_sale": true,
      "company_id": "COMP-001",
      "company_name": "Competitor Co. 1"
    },
    {
      "id": "COMP-MOL-GENE-1",
      "name": "GeneHeal-X (Rare Neuro)",
      "ndc_code": "NDC200",
      "asset_type": "Molecule",
      "development_stage": "Preclinical",
      "therapeutic_area": "Rare Diseases",
      "indication": "Rare Neurodegenerative Disease",
      "mechanism_of_action": "CRISPR-Cas9",
      "route_of_administration": "Intravenous",
      "modality": "Gene Therapy",
      "patent_expiry_year": 2050,
      "current_roi": null,
      "projected_peak_sales_M": null,
      "internal_risk_score": 0.15,
      "efficacy_profile": "Revolutionary potential",
      "safety_profile": "Early stage safety unknown",
      "is_for_sale": true,
      "company_id": "COMP-002",
      "company_name": "Competitor Co. 2"
    },
    {
      "id": "COMP-MOL-PRE-1",
      "name": "NextGenOnco (Pancreatic Cancer)",
      "ndc_code": "NDC300",
      "asset_type": "Molecule",
      "development_stage": "Preclinical",
      "therapeutic_area": "Oncology",
      "indication": "Pancreatic Cancer",
      "mechanism_of_action": "Kinase Inhibitor",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2045,
      "current_roi": null,
      "projected_peak_sales_M": null,
      "internal_risk_score": 0.2,
      "efficacy_profile": "Highly potent in vitro",
      "safety_profile": "No in vivo data",
      "is_for_sale": true,
      "company_id": "COMP-003",
      "company_name": "Competitor Co. 3"
    },
    {
      "id": "COMP-MOL-BACKUP-2",
      "name": "NeuroGuard (Early Alzheimer's)",
      "ndc_code": "NDC400",
      "asset_type": "Molecule",
      "development_stage": "Phase 1",
      "therapeutic_area": "Neuroscience",
      "indication": "Early Alzheimer's",
      "mechanism_of_action": "GPCR Modulator",
      "route_of_administration": "Oral",
      "modality": "Small Molecule",
      "patent_expiry_year": 2042,
      "current_roi": null,
      "projected_peak_sales_M": null,
      "internal_risk_score": 0.35,
      "efficacy_profile": "Promising early data",
      "safety_profile": "Well tolerated so far",
      "is_for_sale": true,
      "company_id": "COMP-004",
      "company_name": "Competitor Co. 4"
    }
  ],
  "external_trial_data": [
    {
      "trial_id": "TRIAL-10001",
      "molecule_id": "MOL-001",
      "indication": "Advanced NSCLC",
      "development_stage": "Phase 2",
      "results_summary": "Met primary endpoint with statistical significance.",
      "safety_profile": "Well tolerated",
      "efficacy_profile": "Strong",
      "target_biology": "EGFR inhibition",
      "pathway_overlap": ["Cell Proliferation", "Apoptosis"],
      "patient_population_characteristics": "Adults with advanced solid tumors"
    },
    {
      "trial_id": "TRIAL-10002",
      "molecule_id": "MOL-002",
      "indication": "Alzheimer's Disease",
      "development_stage": "Phase 3",
      "results_summary": "Showed promising efficacy in subset of patients.",
      "safety_profile": "Mild AEs",
      "efficacy_profile": "Moderate",
      "target_biology": "APP cleavage",
      "pathway_overlap": ["Neurodegeneration"],
      "patient_population_characteristics": "Patients with early-onset Alzheimer's"
    },
    {
      "trial_id": "TRIAL-10003",
      "molecule_id": "COMP-MOL-001",
      "indication": "Type 2 Diabetes",
      "development_stage": "Phase 3",
      "results_summary": "Superior efficacy to current standard of care.",
      "safety_profile": "Very well tolerated",
      "efficacy_profile": "Strong",
      "target_biology": "GPCR modulation",
      "pathway_overlap": ["Metabolic Regulation"],
      "patient_population_characteristics": "Patients with Type 2 Diabetes, uncontrolled on metformin"
    }
  ],
  "market_benchmarks": [
    {
      "therapeutic_area": "Oncology",
      "development_stage": "Preclinical",
      "avg_roi": 0.15,
      "avg_peak_sales_M": 500.0,
      "avg_time_in_stage_months": 24,
      "success_rate": 0.6
    },
    {
      "therapeutic_area": "Oncology",
      "development_stage": "Phase 1",
      "avg_roi": 0.2,
      "avg_peak_sales_M": 750.0,
      "avg_time_in_stage_months": 18,
      "success_rate": 0.4
    },
    {
      "therapeutic_area": "Oncology",
      "development_stage": "Phase 2",
      "avg_roi": 0.25,
      "avg_peak_sales_M": 1000.0,
      "avg_time_in_stage_months": 24,
      "success_rate": 0.25
    },
    {
      "therapeutic_area": "Neuroscience",
      "development_stage": "Phase 3",
      "avg_roi": 0.35,
      "avg_peak_sales_M": 1500.0,
      "avg_time_in_stage_months": 36,
      "success_rate": 0.6
    }
  ],
  "literature_snippets": [
    {"text": "Recent studies indicate that GPCR modulation, traditionally explored for neurological disorders, also shows promise in mitigating inflammatory pathways associated with certain autoimmune conditions like Psoriatic Arthritis.", "source": "PubMedID:12345"},
    {"text": "The EGFR pathway, a well-known target in oncology, has emerging implications in fibrotic diseases, suggesting potential for existing EGFR inhibitors beyond cancer.", "source": "Journal of Fibrosis Research"},
    {"text": "CRISPR-Cas9 gene editing has revolutionized approaches to monogenic rare diseases, with ongoing trials for conditions like Huntington's disease showing early promise.", "source": "Nature Genetics"},
    {"text": "Immunomodulators previously used in rheumatoid arthritis are being repurposed for various dermatological conditions due to shared inflammatory mechanisms.", "source": "Dermatology Today"},
    {"text": "Advances in understanding amyloid-beta plaque formation in Alzheimer's disease have also shed light on related protein misfolding disorders, opening new therapeutic avenues.", "source": "Science Translational Medicine"}
  ]
}